US equities |
SPCX $166.85 ▲+4.96% NVDA $236.75 ▲+1.19% MU $1,063.72 ▼-1.04% TSLA $377.19 ▲+1.78% MSFT $525.20 ▲+1.48% SNDK $1,707.52 ▼-0.73% INTC $117.15 ▼-1.83% META $743.16 ▲+2.07%
FinancialContent

Cyclo Therapeutics, Inc. - Common Stock (NQ:CYTH)

0.7206 UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cyclo Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
From Rafael Holdings, Inc.; Cyclo Therapeutics
Via GlobeNewswire
News headline image
CYTH Stock Earnings: Cyclo Therapeutics Misses EPS, Misses Revenue for Q2 2024 ↗
CYTH stock results show that Cyclo Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer’s Disease from European Patent Office
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential 
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
CYTH Stock Earnings: Cyclo Therapeutics Reported Results for Q1 2024 ↗
Cyclo Therapeutics just reported results for the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
CYTH Stock Earnings: Cyclo Therapeutics Reported Results for Q4 2023 ↗
Cyclo Therapeutics just reported results for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s session after announcing a share repurchase program. 
Via Benzinga
News headline image
Why Bridgeline Digital Shares Are Trading Lower By 13%; Here Are 20 Stocks Moving Premarket ↗
Shares of Bridgeline Digital, Inc. (NASDAQ: BLIN) fell sharply in pre-market following the release of fourth-quarter results. Bridgeline Digital posted a narrower-than-expected loss for its fourth... 
Via Benzinga
Topics Earnings
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results
Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investments 
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results
Company positions itself to generate value for its stockholders by curtailing expenses while increasing investment in strategic opportunities 
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million
From Cyclo Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >